Blueprint Medicines Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 6 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Blueprint Medicines stock.
View analyst ratings for Blueprint Medicines or view top-rated stocks.

Wall Street analysts have given Blueprint Medicines a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Blueprint Medicines wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Blueprint Medicines.

Blueprint Medicines will be holding an earnings conference call on Thursday, July 29th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Blueprint Medicines Co. (NASDAQ:BPMC) announced its earnings results on Wednesday, April, 28th. The biotechnology company reported ($1.72) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.80) by $0.08. The biotechnology company had revenue of $21.58 million for the quarter, compared to analysts' expectations of $24.71 million. Blueprint Medicines had a trailing twelve-month return on equity of 27.25% and a net margin of 40.18%.
View Blueprint Medicines' earnings history.

Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BPMC shares have increased by 61.3% and is now trading at $84.55.
View which stocks have been most impacted by COVID-19.

13 brokerages have issued 12 month price objectives for Blueprint Medicines' shares. Their forecasts range from $81.00 to $152.00. On average, they expect Blueprint Medicines' stock price to reach $116.46 in the next twelve months. This suggests a possible upside of 37.7% from the stock's current price.
View analysts' price targets for Blueprint Medicines or view top-rated stocks among Wall Street analysts.

5 employees have rated Blueprint Medicines CEO Jeff Albers on Glassdoor.com. Jeff Albers has an approval rating of 100% among Blueprint Medicines' employees. This puts Jeff Albers in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Blueprint Medicines include UCB (UCBJF), Catalent (CTLT), Elanco Animal Health (ELAN), Viatris (VTRS), BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Dr. Reddy's Laboratories (RDY), Ono Pharmaceutical (OPHLF), Maravai LifeSciences (MRVI), Grifols (GRFS), CureVac (CVAC), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA) and BridgeBio Pharma (BBIO).
View all of BPMC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines' stock is owned by a number of retail and institutional investors. Top institutional shareholders include EFG Asset Management Americas Corp. (0.01%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Debra Durso-Bumpus, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch, Mark Alan Goldberg and Nicholas Lydon.
View institutional ownership trends for Blueprint Medicines.

BPMC stock was purchased by a variety of institutional investors in the last quarter, including EFG Asset Management Americas Corp..
View insider buying and selling activity for Blueprint Medicines or or view top insider-buying stocks.

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BPMC stock can currently be purchased for approximately $84.55.

Blueprint Medicines has a market capitalization of $4.93 billion and generates $793.73 million in revenue each year. The biotechnology company earns $313.88 million in net income (profit) each year or $5.59 on an earnings per share basis.

Blueprint Medicines employs 451 workers across the globe.

The official website for Blueprint Medicines is www.blueprintmedicines.com.

Blueprint Medicines is headquartered at 45 SIDNEY STREET, CAMBRIDGE MA, 02139.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 374-7580 or via email at [email protected]